Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Zanidatamab Zovodotin (ZW49) in HER2-Expressing Cancers
jRCT2031230641Phase 1Completed
- Sponsor
- Zymeworks Inc.
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of zanidatamab zovodotin in breast cancer, gastroesophageal junction adenocarcinoma and Nonhematologic neoplasms, sponsored by Zymeworks Inc. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence of adverse events and 3 more. Started Mar 2024; status: completed.
02
Drugs
zanidatamab zovodotin
03
Conditions
breast cancergastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230641.